Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the invention relates to novel imidazopyridine derivatives, which are used in the pharmaceutical industry for the production of pharmaceutical compositions.
• the invention thus relates, in a first embodiment (embodiment a), to compounds of formula I
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1-4C-alkoxy; or in which
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which R11 is 1-4C-alkyl, halogen, 1-4C-alkoxy, or mono- or di-1-4C-alkylamino, R12 is 1-4C-alkyl or halogen, R2 is hydrogen, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or 1-4C-alkyl, and R3 is hydrogen, halogen, 1-4C-aIkoxy, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1-4C-alkoxy; or in which R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded,
• R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxy-2-4C-alkyl, mono- or di-1-4C- alkylamino-2-4C-alkyl, phenyl, pyrimidyl, pyridyl, formyl, 3-7C-cycloalkyl, 3-7C-cycloalkyImethyl, or R231- and/or R232 -substituted phenyl, in which R231 is halogen, cyano or 1-4C-alkyl, R232 is halogen or 1-4C-alkyl, and R3 is hydrogen, halogen, 1-4C-alkoxy, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1-4C-alkoxy; and in which
• R4 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy
• R5 is 1-4C-alkyl
• A is 1-4C-alkylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• the invention relates, in a second embodiment (embodiment b), to compounds of formula I, in which
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or in which
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which R11 is 1-4C-aIkyl, halogen, 1-4C-alkoxy, or mono- or di-1-4C-a!kylamino, R12 is 1-4C-alkyl or halogen,
• R2 is hydrogen, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or 1-4C-alkyl
• R3 is hydrogen, halogen, 1-4C-alkoxy, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1-4C-alkoxy; or in which R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het, in which Het is a 3- to 10-membered saturated or partially saturated heterocyclic ring comprising totally 1 to 3 heteroatoms selected from a group consisting of oxygen, sulfur and nitrogen, and optionally substituted by R21 on a ring carbon atom and/or by R22 on a further ring carbon atom and/or by R23 on a ring nitrogen atom, in which R21 is 1 -4C-alkyl, 1-4C-alkoxy or phenylcarbonyl, R22 is 1 -4
• R4 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy
• R5 is 1-4C-alkyl
• A is 1-4C-alkylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• 1-4C-Alkyl is a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, and, particularly, the ethyl and methyl radicals.
• 2-4C-Alkyl is a straight-chain or branched alkyl radical having 2 to 4 carbon atoms. Examples are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl and, particularly, ethyl radical.
• 1-4C-Alkylene is a straight chain alkylene radical having 1 to 4 carbon atoms. Examples which may be mentioned in this context are the methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), trimethylene (-CH 2 -CH 2 -CH 2 -) and the tetramethylene (-CH 2 -CH 2 -CH 2 -CH 2 -) radical.
• 1-4C-Alkoxy is a radical which, in addition to the oxygen atom, contains a straight-chain or branched alkyl radical having 1 to 4 carbon atoms.
• Alkoxy radicals having 1 to 4 carbon atoms which may be mentioned in this context are, for example, the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy, and, particularly, the ethoxy and methoxy radicals.
• 3-7C-Cycloalkyl stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.
• 3-7C-Cycloalkylmethyl stands for a methyl radical, which is substituted by one of the abovementioned 3-7C-cycloalkyl radicals. Examples which may be mentioned are the cyclopropylmethyl and the cyclohexylmethyl radicals.
• Halogen within the meaning of the present invention is bromine, or preferably chlorine or fluorine.
• Completely or predominantly fluorine-substituted 1-4C-alkoxy is, for example, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1 ,2,2-trifluoroethoxy and in particular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and the difluoromethoxy radical, of which the difluoromethoxy radical is preferred.
• "Predominantly" in this connection means that more than half of the hydrogen atoms of the 1-4C-alkoxy groups are replaced by fluorine atoms.
• 1-4C-Alkoxy-2-4C-alkyl stands for one of the abovementioned 2-4C-alkyl radicals which is substituted by one of the abovementioned 1 -4C-alkoxy radicals.
• Examples which may be mentioned are the 2- (methoxy)ethyl (-CH2-CH2-O-CH3), the 3-(methoxy)propyl (-CH2-CH 2 -CH 2 -O-CH 3 ), the 2-(ethoxy)ethyl (-CH 2 -CH 2 -0-CH2-CH 3 ) and the 2-(isopropoxy)ethyl (-CH 2 -CH 2 -0-CH-(CH 3 ) 2 ) radical.
• Hydroxy-2-4C-alkyl stands for one of the abovementioned 2-4C-alkyl radicals which is substituted by an hydroxyl radical. Examples which may be mentioned are the 2-hydroxyethyl and the 3- hydroxypropyl radical.
• Mono- or Di-1-4C-alkylamino radicals contain in addition to the nitrogen atom, one or two of the abovementioned 1-4C-alkyl radicals. Prefened are the di-1-4C-alkylamino radicals, especially the dimethylamino, the diethylamino and the diisopropylamino radical.
• Mono- or Di-1-4C-alkylamino-2-4C-alkyl stands for one of the abovementioned 2-4C-alkyl radicals which is substituted by one of the abovementioned mono- or di-1-4C-alkylamino radicals.
• An example which may be mentioned is the 2-(dimethylamino)ethyl radical.
• Phenyl-1-4C-alkyl stands for one of the abovementioned 1-4C-alkyl radicals, which is substituted by a phenyl radical. Examples which may be mentioned are the phenethyl and the benzyl radical.
• 1-4C-Alkylcarbonyl is a carbonyl group to which one of the abovementioned 1-4C-alkyl radicals is bonded. An example is the acetyl [CH 3 -C(0)-] radical.
• N-oxide denotes the N-oxide on the pyridine which is substituted by -OR5.
• Het refers in a first aspect (aspect a) to a fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated non-aromatic heterocyclic ring B, which heterocyclic ring B comprises one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, and which ring Het is optionally substituted by R21 on a ring carbon atom, and/or which ring Het is optionally substituted by R22 on a further ring carbon atom, and/or which ring Het is optionally substituted by an ethylenedioxy group, and/or which ring Het is optionally substituted by R23 on a ring nitrogen atom.
• a first constituent being a 3- to 7-
• Het may include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl, and the oxo substituted derivatives of the aforementioned examples such as e.g.
• 2-oxopiperazinyl or 5-oxo-1 ,4-diazepanyl, as well as thiomorpholine S-oxide orthiomorpholine S,S- dioxide, and the benzo-fused derivatives of the aforementioned examples such as e.g. indolinyl, isoindolinyl,
• oxo forms a carbonyl moiety when attached at a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
• Het refers in a second aspect (aspect b), which is an embodiment of aspect a, to a 3- to 10-membered saturated or partially saturated heterocyclic ring radical comprising totally 1 to 3 heteroatoms selected from a group consisting of oxygen, sulfur and nitrogen, and optionally substituted by R21 on a ring carbon atom and/or by R22 on a further ring carbon atom and/or by R23 on a ring nitrogen atom.
• Exemplary Het radicals according to aspect b may be optionally substituted by R21 and/or R22 and/or
• R23 and may include, without being restricted thereto, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl, imidazolidin-1-yl, thiomo ⁇ holin-4-yl, homopiperidin-1-yl, homopiperazin-1-yl, indolin-1-yl, isoindolin-1- yl, 1,2,3,4-tetrahydroquinolin-1-yl, piperidin-1-yl, mo ⁇ holin-4-yl, 1,2,3,4-tetrahydroisoquinolin-2-yl, 1,4- diazepan-5-one-1-yl, piperazin-3-one-1-yl, or 1,4-dioxa-8-azaspiro[4.5]decan-8-yl.
• Het according to aspect b can be mentioned, without being restricted thereto, piperidin-1-yl, mo ⁇ holin-4-yl, azetidin-1-yl, pyrrolidin-1-yl, or 1,4-dioxa-8-azaspiro[4.5]decan-8-yl.
• R21 is 1 ⁇ 4C-alkyl or phenylcarbonyl, such as, for example, 4-methyl-piperidin-1-yl, or 4-benzoyl-piperidin-1-yl;
• R21 is 1-4C-alkoxy
• R22 is 1-4C-alkoxy, such as, for example, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl, or 6,7-diethoxy-1, 2,3,4- tetrahydroisoquinolin-2-yl; piperazin-1-yl substituted by R23 on 4-N, suitably in which
• R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1 -4C-alkoxy-2-4C-alkyl, mono- or di-1-4C- alkylamino-2-4C-alkyl, phenyl, pyrimidyl, pyridyl, formyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl methyl, or R231- and/or R232 -substituted phenyl, in which R231 is halogen, cyano or 1-4C-alkyl, and R232 is halogen or 1-4C-alkyl, and preferably in which R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, or R231- and/or R232-substituted pheny
• R23 is 1-4C-alkyl, such as, for example, 4-N-methyl-homopiperazin-1-yl.
• Suitable salts for compounds of the formula I - depending on substitution - are all acid addition salts or all salts with bases. Particular mention may be made of the pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy. Those suitable are, on the one hand, water- insoluble and, particularly, water-soluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid or 3-hydroxy-2-naphthoic acid, the acids being employed in
• salts with bases are - depending on substitution - also suitable.
• salts with bases are mentioned the lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, meglumine or guanidinium salts, here, too, the bases being employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
• Pharmacologically intolerable salts which can be obtained, for example, as process products during the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
• the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I as well as all solvates and in particular all hydrates of the salts of the compounds of formula I.
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1-4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or in which
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which
• R11 is 1-4C-alkyl, halogen, 1-4C-alkoxy, or di-1-4C-alkylamino,
• R12 is 1 -4C-alkyl or halogen
• R2 is hydrogen, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or 1-4C-alkyl, and
• R3 is hydrogen, halogen, 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy; or in which
• Het is a fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated non-aromatic heterocyclic ring B, which heterocyclic ring B is piperazine, mo ⁇ holine, thiomo ⁇ holine, homopiperazine, piperidine, pyrrolidine or azetidine, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, and which ring Het is optionally substituted by R21 on a ring carbon atom, and/or which ring Het is optionally substituted by R22 on a further ring carbon atom, and/or which ring Het is optionally substituted by an ethylenedioxy group, and/or which ring Het is optionally substituted by R23 on a ring nitrogen atom, in which
• R21 is 1-4C-alkyl, 1-4C-alkoxy or phenylcarbonyl,
• R22 is 1-4C-alkyl or 1-4C-alkoxy
• R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, or R231- and/or R232-substituted phenyl, in which
• R231 is halogen, cyano or 1-4C-alkyl
• R232 is halogen or 1-4C-alkyl
• R3 is hydrogen, halogen, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy; and in which R4 is hydrogen, or 1-4C-alkyl.
• R5 is methyl
• A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or
• R1 is 3-7C-cycloalkyl, phenyl-1 -4C-alkyl, hydroxy-2-4C-alkyl, phenyl, pyridyl, or R11 - and/or R12- substituted phenyl, in which either
• R11 is 1-4C-alkyl, 1-4C-alkoxy, or mono- or di-1-4C-alkylamino, and R12 is halogen, or
• R11 is halogen, 1-4C-alkoxy, or mono- or di-1-4C-alkylamino, and R12 is 1-4C-alkyl,
• R2 is hydrogen, hydroxy-2-4C-alkyl or 1-4C-alkyl
• R3 is hydrogen, halogen, 1-4C-alkoxy, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het, in which Het is optionally substituted by R21 on a ring carbon atom and/or by R22 on a further ring carbon atom and/or by R23 on a ring nitrogen atom and is azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl, thiomorpholin-4-yl, homopiperidin-1-yl, homopiperazin-1-yl, indolin-1-yl, isoindolin-1-yl, 1,2,3,4- tetrahydroquinolin-2-y
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or in which
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2 ⁇ C-alkyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which
• R11 is 1-4C-alkyl, halogen, 1-4C-alkoxy, ordi-1-4C-alkylamino,
• R12 is 1 -4C-alkyl or halogen
• R2 is hydrogen, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or 1-4C-alkyl, and
• R3 is hydrogen, halogen, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy; or in which
• Het is piperidinyl, pyrrolidinyl or azetidinyl, or morpholinyl, thiomorpholinyl, S-oxo-thiomorpholinyl or S,S-dioxo-thiomorpholinyl, or 1 ,2,3,4-tetrahydroisoquinolinyl or di-(1-4C-alkoxy)-1 ,2,3,4-tetrahydroisoquinolinyl, or piperidinyl substituted by either ethylenedioxy or R21, or 4N-(R23)-piperazinyl or4N-(R23)-homopiperazinyl, or 4N-(H)-1 ,4-diazepan-5-one-1-yl or 4N-(R23)-1 ,4-diazepan-5-one-1-yl, in which
• R21 is 1-4C-alkyl, or phenylcarbonyl
• R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, or R231- and/or R232-substituted phenyl, in which
• R231 is halogen, cyano or 1-4C-alkyl
• R232 is halogen or 1-4C-alkyl
• R3 is hydrogen, halogen, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy;
• R4 is hydrogen, or 1-4C-alkyl
• R5 is methyl
• A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• Compounds according to embodiment b of this invention more worthy to be mentioned are compounds of formula I, in which
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, phenyl, pyridyl, or R11- and/or R12- substituted phenyl, in which either
• R11 is 1-4C-alkyl, 1-4C-alkoxy, or mono- or di-1-4C-alkylamino, and R12 is halogen, or
• R11 is halogen, 1-4C-alkoxy, or mono- or di-1-4C-alkylamino, and R12 is 1-4C-alkyl,
• R2 is hydrogen, hydroxy-2-4C-alkyl or 1 -4C-alkyl, and R3 is halogen, 1-4C-alkyl, trifluoromethyl, completely or predominantly fluorine-substituted 1-4C- alkoxy, or, particularly, hydrogen; or R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het, in which Het is piperidin-1-yl, or piperidin-1-yl substituted by R21 , in which R21 is 1 -4C-alkyl or phenylcarbonyl, or
• Het is 1 ,2,3,4-tetrahydroisoquinolin-2-yl substituted by R21 and R22, in which R21 is 1-4C-alkoxy, R22 is 1-4C-alkoxy, or
• Het is piperazin-1-yl substituted by R23 on 4-N, in which R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, or R231- and/or R232-substituted phenyl, in which R231 is halogen, cyano or 1-4C-alkyl, R232 is halogen or 1-4C-alkyl, or
• Het is 1 ,4-diazepan-5-one-1-yl, or 1 ,4-diazepan-5-one-1-yl substituted by R23 on 4-N, in which R23 is 1 -4C-alkyl or phenyl-1-4C-alkyl, or
• Het is homopiperazin-1 -yl substituted by R23 on 4-N, in which R23 is 1-4C-alkyl, or Het is mo ⁇ holin-4-yl, azetidin-1-yl, pyrrolidin-1-yl, or 1 ,4-dioxa-8-azaspiro[4.5]decan-8-yl, and
• R3 is hydrogen, halogen, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy;
• R4 is hydrogen
• R5 is methyl
• A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• R1 is hydrogen or 1 -4C-alkyl
• R2 is hydrogen or 1 -4C-alkyl
• R3 is 1 -4C-alkyl, trifluoromethyl, or completely or predominantly fluorine-substituted 1 -4C-alkoxy; or in which
• R1 is 3-7C-cycloalkyl, phenyl-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which either
• R11 is 1-4C-alkyl, 1-4C-alkoxy, or di-1-4C-alkylamino
• R12 is halogen
• R11 is halogen, 1-4C-alkoxy, or di-1-4C-alkylamino
• R12 is 1-4C-alkyl
• R2 is hydrogen, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or 1-4C-alkyl, and
• R3 is hydrogen; or in which
• Het is piperidinyl, pyrrolidinyl or azetidinyl, or morpholinyl, thiomorpholinyl, S-oxo-thiomorpholinyl or S,S-dioxo-thiomo ⁇ holinyl, or 1,2,3,4-tetrahydroisoquinolinyl or di-(1-4C-alkoxy)-1 ,2,3,4-tetrahydroisoquinolinyl, or piperidinyl substituted by either ethylenedioxy or R21, or 4N-(R23)-piperazinyl or4N-(1-4C-alkyl)-homopiperazinyl, or 4N-(H)-1 ,4-diazepan-5-one-1 -yl, 4N-(phenyl-1 -4C-alkyl)-1 ,4-diazepan-5-one-1 -yl or 4N-(1 - 4C-alkyl)-1
• R21 is 1-4C-alkyl, or phenylcarbonyl
• R23 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkylcarbonyl, 1 -4C-alkoxy-2-4C-alkyl, phenyl, or R231- and/or R232-substituted phenyl, in which
• R231 is halogen, cyano or 1-4C-alkyl
• R232 is halogen or 1-4C-alkyl
• R3 is hydrogen, halogen, 1-4C-alkyl, trifluoromethyl, or completely or predominantly fluorine- substituted 1-4C-alkoxy
• R4 is hydrogen, or 1 -4C-alkyl, R5 is methyl, A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• R1 is methyl
• R2 is methyl
• R3 is methyl, trifluoromethyl or trifluoromethoxy
• R1 is cyclohexyl, benzyl, 2-hydroxyethyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which either
• R11 is methyl, methoxy or dimethylamino
• R12 is chlorine or fluorine
• R11 is chlorine, fluorine, methoxy or dimethylamino, and R12 is methyl
• R2 is hydrogen or methyl
• R1 and R2 are both 2-hydroxyethyl
• R3 is hydrogen
• R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het, in which Het is piperidin-1-yl, or piperidin-1-yl substituted by R21, in which R21 is methyl or phenylcarbonyl, or
• Het is 1 ,2,3,4-tetrahydroisoquinolin-2-yl substituted by R21 and R22, in which R21 is methoxy, R22 is methoxy, or
• Het is piperazin-1-yl substituted by R23 on 4-N, in which R23 is methyl, ethyl, benzyl, phenethyl, acetyl, 2-methoxyethyl, phenyl, or R231- and/or R232- substituted phenyl, in which R231 is chlorine, cyano or methyl, R232 is chlorine or methyl, or
• Het is 1,4-diazepan-5-one-1-yl, or 1,4-diazepan-5-one-1-yl substituted by R23 on 4-N, in which
• R23 is methyl, ethyl or benzyl, or
• Het is homopiperazin-1-yl substituted by R23 on 4-N, in which
• R23 is methyl, or
• Het is morpholin-4-yl, azetidin-1-yl, pyrrolidin-1-yl, or 1,4-dioxa-8-azaspiro[4.5]decan-8-yl, and
• R3 is hydrogen, fluorine, chlorine, methyl, trifluoromethyl or trifluoromethoxy
• R4 is hydrogen
• R5 is methyl
• A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• R1 is methyl
• R2 is methyl
• R3 is methyl, trifluoromethyl, or trifluoromethoxy
• R1 is cyclohexyl, cyclobutyl, cyclopropyl, benzyl, 2-hydroxy-ethyl, 2-methoxy-ethyl, phenyl, pyridyl, or R11- and/or R12-substituted phenyl, in which either
• R11 is methyl, methoxy, or dimethylamino
• R12 is fluorine, or
• R11 is fluorine, chlorine, methoxy, or dimethylamino, and R12 is methyl,
• R2 is hydrogen, 2-hydroxy-ethyl, 2-methoxy-ethyl, or methyl
• R3 is hydrogen; or in which R1 and R2 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het, in which Het is piperidinyl, pyrrolidinyl or azetidinyl, or morpholinyl, thiomorpholinyl, S-oxo-thiomorpholinyl or S,S-dioxo-thiomo ⁇ holinyl, or 1,2,3,4-tetrahydroisoquinolinyl, di-methoxy-1 ,2,3,4-tetrahydroisoquinolinyl, or di-ethoxy- 1 ,2,3,4-tetrahydroisoquinolinyl, or 4,4-ethylenedioxy-piperidinyl or 4-(R21)-piperidinyl, or 4N-(R23)-piperaz
• R231 is chlorine, cyano or methyl, and R232 is chlorine, or
• R231 is chlorine, cyano or methyl, and R232 is methyl, and
• R3 is hydrogen, fluorine, chlorine, methyl, trifluoromethyl, or trifluoromethoxy
• R4 is hydrogen, or methyl, R5 is methyl, A is ethylene; the salts, N-oxides and the salts of the N-oxides of these compounds.
• a special embodiment of the compounds of the present invention include those compounds of formula I in which R5 is methyl.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which A is ethylene.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which R5 is methyl and A is ethylene.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which R4 is hydrogen.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which R4 is methyl.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which R4 is hydrogen, R5 is methyl and A is ethylene.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which R4 is methyl, R5 is methyl and A is ethylene.
• Another special embodiment of the compounds of the present invention include those compounds of formula I in which the aminosulphonylphenyl moiety is bonded to the 6-position of the imidazopyridine ring system.
• the substituent R3 and the aminosulphonyl radical of compounds according to this invention can be attached in the ortho, meta or para position with respect to the binding position in which the phenyl ring is bonded to the imidazopyridine ring system, whereby a special embodiment of the compounds of the present invention include those compounds of formula I in which the aminosulphonyl radical is attached in the meta or, particularly, para position.
• another embodiment of the compounds of the present invention include those compounds of formula I in which R3 is attached in the ortho or meta position and the aminosulphonyl radical is attached in the para position with respect to the binding position in which the phenyl ring is bonded to the imidazopyridine ring system.
• the substituents R11 and R12 of compounds according to this invention can be attached in the ortho, meta or para position with respect to the binding position in which the phenyl ring is bonded to the nitrogen atom.
• the substituents R231 and R232 of compounds according to this invention can be attached in the ortho, meta or para position with respect to the binding position in which the phenyl ring is bonded to the ring nitrogen atom.
• reaction scheme 1 a compound of formula II, in which R4, R5 and A have the meanings given above and X is a suitable leaving group, preferably bromine or, particularly, iodine, is reacted with boronic acids or, particularly, boronic acid esters (e.g.
• pinacol esters of formula III, in which R1, R2 and R3 have the meanings given above and Y is a boronic acid group or, particularly, a boronic acid ester group, suitably a cyclic boronic acid ester group such as, for example, the boronic acid pinacol ester group, under conditions appropriate for a Suzuki reaction to occur to give compounds of formula I, in which R1, R2, R3, R4, R5 and A have the meanings mentioned above.
• the Suzuki reaction is carried out as it is known to the person of ordinary skill in the art and/or in a manner as it is described below and specified by way of example in the following examples or analogously or similarly thereto.
• the Suzuki reaction mentioned can be carried out in organic solvents alone, for example in toluene, benzene, dimethylformamide or in ethereal (e.g. dimethoxyethane or, in particular, dioxane) or alcohol solvents or in a mixture thereof, or preferably in a mixture comprising an organic solvent (in particular dioxane) and water, with organic (e.g. triethylamine) or preferably inorganic base (e.g.
• a transition metal catalyst for example, a nickel or, in particular, palladium catalyst (e.g. Pd(OAc) 2 , PdCI (PPh 3 ) 2 or, in particular, Pd(PPh 3 ) 4 ), and, optionally, lithium chloride.
• a transition metal catalyst for example, a nickel or, in particular, palladium catalyst (e.g. Pd(OAc) 2 , PdCI (PPh 3 ) 2 or, in particular, Pd(PPh 3 ) 4 ), and, optionally, lithium chloride.
• the reaction is carried out at a temperature in the range from 20° to 160°C, usually 60° to 130°C for 10 minutes to 5 days, usually 30 minutes to 24 hours.
• the solvents used are degassed and the reaction is carried out under protective gas.
• Suzuki reaction is for example described in Tetrahedron Lett. 1998, 39, 4467, J. Org. Chem. 1999, 64, 1372 or Heterocycles 1992, 34, 1395.
• a general review of Suzuki cross-couplings between boronic acids and aryl halides can be found in Miyaura, N; Suzuki, A. Chem. Rev. 1995, 95, 2457.
• Boronic acids or boronic acid esters (e.g. pinacol esters) of formula III are known or can be obtained in an art-known manner or analogously or similarly to known compounds.
• Boronic acid esters (e.g. pinacol esters) of formula III can be prepared, for example, as described in the following examples starting from phenyl triflates or, particularly, phenyl halides, preferably the bromides or iodides, using e.g. bis-(pinacolato)-diboron in the presence of a transition metal, preferably palladium, catalyst.
• the boronic acid esters obtained can be isolated or, preferably, they are generated in situ and used in the subsequent Suzuki reaction without isolation.
• the carbon chain in 2-position of the compounds of formula VII is lengthened, for example, by a condensation (with a malonic acid derivative) and a subsequent hydrogenation reaction.
• the carbon chain can be lengthened using a Wittig reaction followed by a hydrogenation reaction.
• Compounds of formula VII can be also prepared starting from commercially available 4-nitro-2- picoline-N-oxide by exchange of the nitro group by an 1-4C-alkoxy group.
• the resulting 4-(1-4C)- alkoxy-2-picoline-N-oxide is then via a rearrangement and an oxidation step converted to 4-(1-4C)- alkoxy-pyridin-2-carbaldehyd (compound of formula VII).
• compounds of formula I can be converted into their salts, or, optionally, salts of the compounds of formula I can be converted into the free compounds.
• Corresponding processes are known to the person skilled in the art.
• the compounds of formula I according to this invention can be converted, optionally, into their N- oxides, for example with the aid of hydrogen peroxide in methanol or with the aid of m- chloroperoxybenzoic acid in dichloromethane.
• the person skilled in the art is familiar on the basis of his/her expert knowledge with the reaction conditions which are specifically necessary for carrying out the N-oxidation.
• the substances according to the invention are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as column chromatography on a suitable support material.
• Salts are obtained by dissolving the free compound in a suitable solvent (for example a ketone like acetone, methylethylketone, or methylisobutylketone, an ether, like diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol, such as ethanol, isopropanol) which contains the desired acid, or to which the desired acid is then added.
• a suitable solvent for example a ketone like acetone, methylethylketone, or methylisobutylketone, an ether, like diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol, such as ethanol, isopropanol
• Salts obtained can be converted by basi- fication into the free compounds which, in turn, can be converted into salts.
• pharmacologically non-tolerable salts can be converted into pharmacologically tolerable salts.
• the conversions mentioned in this invention can be carried out analogously or similarly to methods which are familiar per se to the person skilled in the art, for example, in the manner which is described by way of example in the following examples.
• m.p. stands for melting point, h for hours, d for days, min for minutes, TLC for thin layer chromatography, Rf for retention factor, MS for mass spectrum, M for molecular ion, other abbreviations have their meanings customary per se for the skilled person.
• starting material A1 2-[2-(4-methoxypyridin-2-yl)ethyl]-6-iodo-3H-imidazo[4,5-b]pyridine (starting material A1) and the appropriate boronic acid or boronic acid ester derivatives, which can be prepared in a manner known to the person skilled in the art or analogously or similarly as described in the examples above, such as e.g. in situ from the appropriate bromo-benzenesulfonamide derivatives, the following compounds can be obtained according to the procedures as described by way of example in the abovementioned examples or analogously or similarly thereto.
• Nitric oxide synthases are enzymes that generate NO and citrulline from the amino acid arginine. In certain pathophysiological situations such as arginine depletion or tetrahydrobiopterin depletion the generation of 0 2 * from NO-synthases instead or together with NO has been reported. NO is long known as a signalling molecule in most living organisms including mammals and humans.
• NO-synthases The most prominent action of NO is it's smooth muscle relaxing activity, which is caused on the molecular level by the activation of soluble guanylate cyclase. In the last years a lot of other enzymes have been shown to be regulated by NO or reaction products of NO. There exist three isoforms of NO-synthases which fall into two classes and differ in their physiologic functions and molecular properties.
• the first class known as constitutive NO-synthases, comprises of the endothelial NO-synthase and the neuronal NO-synthase.
• Both isoenzymes are expressed constitutively in various cell types, but are most prominent in endothelial cells of blood vessel walls (therefore called endothelial NO-synthase, eNOS or NOS-III) and in neuronal cells (therefore called neuronal NO-synthase, nNOS or NOS-I). Activation of these two enzymes is dependent on Ca 2+ /Calmodulin which is generated by transient increases of the intracellular free Ca 2 * concentration. Activation of constitutive isoforms leads to transient bursts of nitric oxide resulting in nanomolar cellular or tissue NO concentrations. The endothelial isoform is involved in the physiologic regulation of blood pressure. NO generated by the neuronal isoform seems to have neurotransmitter function and the neuronal isoform is among other regulatory processes involved in memory function (long term potentiation).
• inducible NO-synthase the sole member of the second class, is performed by transcriptional activation of the iN OS-promoter.
• Proinflammatory stimuli lead to transcription of the gene for inducible NO-synthase, which is catalytically active without increases in the intracellular Ca ⁇ -concentration. Due to the long half live of the inducible NO-synthase and the unregulated activity of the enzyme, high micromolar concentrations of NO are generated over longer time periods. These high NO-concentrations alone or in cooperation with other reactive radicals such as 0 2 " are cytotoxic Therefore, in situations of microbial infections, iNOS is involved in cell killing by macrophages and other immune cells during early nonspecific immune responses.
• LPS- induced experimental lung injury is reduced by inhibition of inducible NO-synthase or in iNOS-knock out mice (Kristof et al. Am. J. Crit. Care. Med. 158, 1883-1889, 1998).
• a pathophysiological role of inducible NO-synthase derived NO or 0 2 " is also discussed in chronic inflammatory diseases such as asthma, bronchitis and COPD.
• nitric oxide as a potential mediator of microglia dependent primary demyelination, a hallmark of multiple sklerosis (Parkinson et al. J. Mol. Med. 75, 174-186, 1997).
• An inflammatory reaction with concomitant expression of inducible NO-synthase also takes place during cerebral ischemia and reperfusion (ladecola et al. Stroke 27, 1373-1380, 1996). Resulting NO together with 0 2 " from infiltrating neutrophils is thought to be responsible for cellular and organ damage.
• NO-synthase inhibitors have been show to posses protective properties.
• a regulatory role for inducible NO-synthase has been reported in various tumor cell lines (Tozer & Everett Clin Oncol. 9. 357-264, 1997).
• the compounds according to the invention can be employed in human and veterinary medicine and therapeutics, where an excess of NO or 0 2 " due to increases in the activity of inducible NO-synthase is involved. They can be used without limitation for the treatment and prophylaxis of the following diseases:
• Acute inflammatory diseases Septic shock, sepsis, SIRS, hemorrhagic shock, shock states induced by cytokine therapy (IL-2, TNF), organ transplantation and transplant rejection, head trauma, acute lung injury, ARDS, inflammatory skin conditions such as sunburn, inflammatory eye conditions such as uveitis, glaucoma and conjunctivitis.
• IL-2 cytokine therapy
• TNF cytokine therapy
• ARDS inflammatory skin conditions such as sunburn
• inflammatory eye conditions such as uveitis, glaucoma and conjunctivitis.
• Chronic inflammatory diseases of peripheral organs and the CNS gastrointestinal inflammatory diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, lung inflammatory diseases such as asthma and COPD, arthritic disorders such as rheumatoid arthritis, osteoarthritis and gouty arthritis, heart disorders such as cardiomyopathy and myocarditis, artherosklerosis, neurogenic inflammation, skin diseases such as psoriasis, dermatitis and eczema, diabetes, glomerulonephritis; dementias such as dementias of the Alzheimer's type, vascular dementia, dementia due to a general medical condition, such as AIDS-, Parkinson's disease, Huntington's induced dementias, ALS, multiple sklerosis; necrotizing vasculitides such as polyarteritis nodosa, serum sickness, Wegener's granulomatosis, Kawasaki ' s syndrom; headaches such as migraine, chronic tension headaches, cluster and vascular headaches
• the compounds may also be useful in the treatment of cancers that express nitric oxide synthase.
• the invention further relates to a method for the treatment of mammals, including humans, which are suffering from one of the abovementioned illnesses.
• the method is characterized in that a therapeuti- cally active and pharmacologically effective and tolerable amount of one or more of the compounds according to the invention is administered to the ill mammal.
• the invention further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of illnesses, especially the illnesses mentioned.
• the invention also relates to the use of the compounds according to the invention for the production of pharmaceutical compositions which are employed for the treatment and/or prophylaxis of the illnesses mentioned.
• the invention also relates to the use of the compounds according to the invention for the production of pharmaceutical compositions having an iNOS inhibitory activity.
• the invention furthermore relates to pharmaceutical compositions for the treatment and/or prophylaxis of the illnesses mentioned, which contain one or more of the compounds according to the invention.
• the invention moreover relates to pharmaceutical compositions according to this invention having an iNOS inhibitory activity.
• compositions are prepared by processes which are known perse and familiar to the person skilled in the art.
• suitable pharmaceutical auxiliaries and/or excipients e.g. in the form of tablets, coated tablets, capsules, capiets, suppositories, patches (e.g. as TTS), emulsions, suspensions, gels or solutions
• auxiliaries or excipients which are suitable for the desired pharmaceutical formulations on account of his/her expert knowledge.
• solvents for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers, colorants, complexing agents or permeation promoters, can be used.
• compositions according to the invention may be performed in any of the generally accepted modes of administration available in the art.
• suitable modes of administration include intravenous, oral, nasal, parenteral, topical, transdermal and rectal delivery. Oral and intravenous delivery are preferred.
• the compounds according to the invention are preferably also administered by inhalation in the form of an aerosol; the aerosol particles of solid, liquid or mixed composition preferably having a diameter of 0.5 to 10 ⁇ m, advantagously of 2 to 6 ⁇ m.
• Aerosol generation can be carried out, for example, by pressure-driven jet atomizers or ultrasonic atomizers, but advantageously by propellant-driven metered aerosols or propellant-free administration of micronized active compounds from inhalation capsules.
• the administration forms additionally contain the required excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
• propellants e.g. Frigen in the case of metered aerosols
• surface-active substances e.g. Frigen in the case of metered aerosols
• emulsifiers emulsifiers
• stabilizers emulsifiers
• preservatives e.g., emulsifiers, stabilizers, preservatives
• flavorings e.g. lactose in the case of powder inhalers
• fillers e.g. lactose in the case of powder inhalers
• the compounds according to the invention are in particular administered in the form of those pharmaceutical compositions which are suitable for topical application.
• suitable pharmaceutical formulations are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
• compositions according to the invention are prepared by processes known perse.
• the dosage of the active compounds is carried out in the order of magnitude customary for iNOS inhibitors.
• Topical application forms (such as ointments) for the treatment of dermatoses thus contain the active compounds in a concentration of, for example, 0.1-99%.
• the dose for administration by inhalation is customarly between 0.1 and 10 mg per day.
• the customary dose in the case of systemic therapy (p.o.) is between 0.3 and 30 mg/kg per day, (i. v.) is between 0.3 and 30 mg/kg/h.
• the assay is performed in 96-well microtiter F-plates (Greiner, Frickenhausen, FRG) in a total volume of 100 ⁇ l in the presence of 100 nM calmodulin, 226 ⁇ M CaCI 2 , 477 ⁇ M MgCI 2 , 5 ⁇ M flavin-adenine- dinucleotide (FAD), 5 ⁇ M flavin mononucleotide (FMN), 0.1 mM NADPH, 7 mM glutathione, 10 ⁇ M BH4 and 100 mM * HEPES pH 7.2. Arginine concentrations are 0.1 ⁇ M for enzyme inhibition experiments. 150000 dpm of [ 3 H]arginine are added to the assay mixture.
• Enzyme reaction is started by the addition of 4 ⁇ g of a crude cytosolic fraction containing human inducible NO-synthase and the reaction mixture is incubated for 45 to 60 min at 37°C. Enzyme reaction is stopped by adding 10 ⁇ l of 2M MES-buffer pH 5,0. 50 ⁇ l of the incubation mixture are transferred into a MADP N65 filtration microtiter plate (Millipore, Eschborn, FRG) containing already 50 ⁇ l of AG-50W-X8 cation exchange resin (Biorad, M ⁇ nchen, FRG).
• the resin in the Na loaded form is pre-equilibrated in water and 70 ⁇ l (corresponding to 50 ⁇ l dry beads) are pipetted under heavy stirring with a 8 channel pipette into the filtration plate. After pipetting 50 ⁇ l of the enzyme reaction mixture onto the filtration plates, the plates are placed on a filtration manifold (Porvair, Shepperton, UK) and the flow through is collected in Pico scintillation plates (Packard, Meriden, CT). The resin in the filtration plates is washed with 75 ⁇ l of water (1x50 ⁇ l and 1x 25 ⁇ l) which is also collected in the same plate as the sample.
• the total flow through of 125 ⁇ l is mixed with 175 ⁇ l of Microscint-40 scintillation cocktail (Packard) and the scintillation plate is sealed with TopSeal P-foil (Packard). Scintillation plates are counted in a szintillation counter.
• Packard Microscint-40 scintillation cocktail
• TopSeal P-foil Packard

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Immunology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Pulmonology (AREA)
• Psychology (AREA)
• Urology & Nephrology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Ophthalmology & Optometry (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Psychiatry (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=34384570

Family Applications (1)

Country Status (19)

Cited By (14)

Families Citing this family (2)

Citations (3)

Family Cites Families (9)

• 2004
  • 2004-09-30 RS YUP-2006/0200A patent/RS20060200A/sr unknown
  • 2004-09-30 CA CA002540243A patent/CA2540243A1/en not_active Abandoned
  • 2004-09-30 ES ES04787262T patent/ES2308260T3/es not_active Expired - Lifetime
  • 2004-09-30 DE DE602004014628T patent/DE602004014628D1/de not_active Expired - Lifetime
  • 2004-09-30 JP JP2006530263A patent/JP2007507466A/ja not_active Withdrawn
  • 2004-09-30 AU AU2004276014A patent/AU2004276014A1/en not_active Abandoned
  • 2004-09-30 NZ NZ546435A patent/NZ546435A/en unknown
  • 2004-09-30 US US10/573,202 patent/US7279488B2/en not_active Expired - Fee Related
  • 2004-09-30 EP EP04787262A patent/EP1670796B1/en not_active Expired - Lifetime
  • 2004-09-30 WO PCT/EP2004/052377 patent/WO2005030770A1/en not_active Ceased
  • 2004-09-30 BR BRPI0414933-5A patent/BRPI0414933A/pt not_active IP Right Cessation
  • 2004-09-30 KR KR1020067005902A patent/KR20060092297A/ko not_active Withdrawn
  • 2004-09-30 MX MXPA06003351A patent/MXPA06003351A/es not_active Application Discontinuation
  • 2004-09-30 EA EA200600607A patent/EA200600607A1/ru unknown
  • 2004-09-30 CN CNB2004800278331A patent/CN100422182C/zh not_active Expired - Fee Related
  • 2004-09-30 AT AT04787262T patent/ATE399168T1/de not_active IP Right Cessation
• 2006
  • 2006-02-19 IL IL173810A patent/IL173810A0/en unknown
  • 2006-02-22 ZA ZA200601553A patent/ZA200601553B/en unknown
  • 2006-03-23 NO NO20061317A patent/NO20061317L/no not_active Application Discontinuation
• 2007
  • 2007-09-27 US US11/905,033 patent/US7709488B2/en not_active Expired - Fee Related
• 2010
  • 2010-05-03 US US12/772,455 patent/US20100216790A1/en not_active Abandoned

Patent Citations (3)

Also Published As

Similar Documents

Legal Events